ClinicalTrials.gg
CompletedNCT04432597Updated Aug 18, 2026Results posted

HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated Cancers

A Phase 1/2 interventional study of PRGN-2009 and M7824 in HPV Positive Cancer, Vulvar, Vaginal, Penile, Rectal Cancer and Anal Cancer, sponsored by National Cancer Institute (NCI). Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-18.

Primary conditionAnus NeoplasmsRegistry: Rectal NeoplasmsReclassifiedWhy we changed it
Registry
Rectal Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Anus Neoplasms
Why
  1. The study's listed conditions name Anus Neoplasms, a narrower term within Rectal Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by National Cancer Institute (NCI) · Phase 1/2, Interventional, and Treatment

How we know · 4 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
39
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies in Anus Neoplasms by National Cancer Institute (NCI) — none open to participants now, 5 under way, 2 of them phase 3. Anus Neoplasms · National Cancer Institute (NCI).

Enrollment
12th of 20
39 · median 41
Started
2020
with 2 others
Phase 1/2
5 of 23
none open now
Registered
19th of 23
by date

Among the 23 studies in Anus Neoplasms by National Cancer Institute (NCI), this one is the 12th largest by enrollment of the 20 interventional ones that give a count, is one of 3 that started in 2020, is one of 5 in phase 1/2, and was the 19th registered.

Anus Neoplasms

298 studies on the registry are indexed under Anus Neoplasms; 75 are open to participants now.

Browse Anus Neoplasms studies →

Open to participants now

None of the 23 studies in Anus Neoplasms by National Cancer Institute (NCI) is open now. The open studies under Anus Neoplasms, anywhere →

Who these studies take

Of the 57 Anus Neoplasms studies recruiting now, 46 (81%) set no upper age limit and 7 (12%) stop at 75 or younger; 3 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 23 studies in Anus Neoplasms by National Cancer Institute (NCI) as a file.
02

Study summary

Background:

For some cancers associated with human papillomavirus (HPV), standard treatments are not helpful. Researchers want to see if a vaccine for HPV combined with a drug called M7824 (MSB0011359C) has a better effect on these cancers than when they work alone.

Objective:

To find a safe dose of HPV vaccine alone or combined with M7824. Also, to test if either HPV vaccine alone or combined with M7824 causes a better immune response.

Eligibility:

People ages 18 and older with locally advanced or metastatic HPV associated cancer (Phase I) or stage II or III p16-positive oropharyngeal cancer (Phase II)

Design:

Participants will be screened with:

Medical history

Physical exam

Blood, urine, and heart tests

Possible photos of skin lesions

Computed tomography (CT), magnetic resonance imaging (MRI), or nuclear bone scan: Participants will lie in a machine that takes pictures of the body. For the CT scan, they may have a contrast agent injected into a vein.

Participants may have up to 2 tumor biopsies. For participants in Phase II, this may be performed with a thin tube placed through the nose into the airway.

Participants will receive the HPV vaccine alone or with M7824. For participants on the Phase II, they will receive two doses of HPV vaccine under the skin either alone or with M7824 as an infusion spaced two weeks apart. This will be done prior to their planned chemoradiation or surgery. For participants on the Phase I, they will get the HPV vaccine injected under the skin 2 to 3 times in the first month. Then they will have a booster every 4 weeks. They will receive M7824 as an infusion into a vein every 2 weeks. Treatment will last up to 1 year.

After they stop treatment, participants will have a visit within 4 weeks. They will then be contacted for long-term follow-up every year, for the rest of their lives.

...

Read the detailed description

Background

  • Metastatic human papillomavirus (HPV) associated malignancies (cervical, anal, oropharyngeal cancers, etc.) are often incurable and poorly palliated by standard therapies.
  • HPV-positive (p16+) oropharyngeal cancers are the most common HPV-associated malignancy in the United States and are increasing in incidence.
  • Stage II and III HPV-positive oropharyngeal cancer is primarily treated with definitive therapy.
  • Although the prognosis for stage I HPV+ oropharyngeal cancer is favorable, about 20 percent of patients with stage II disease and 35 percent of patients with stage III disease will die within four years.
  • Attempts to de-intensify treatment of HPV-positive oropharyngeal cancer by replacing high-dose cisplatin with cetuximab concurrent with radiotherapy have failed.
  • Induction and neoadjuvant immunotherapy are an area of active study in this type of cancer. The aims of induction immunotherapy are to induce antigen-specific immunity prior to definitive therapy and to reduce the risk of disease relapse for patients with stage II and III disease.
  • Therapeutic vaccines targeting HPV alone or in combination with M7824 (MSB0011359C) (dual programmed death-ligand 1 (PD-L1) and transforming growth factor beta (TGF- beta) inhibitor) have demonstrated induction of HPV antigen-specific responses and tumor growth inhibition in multiple pre-clinical models of HPV-positive malignancy.
  • In clinical studies done in the Center for Cancer Research (CCR), M7824 as monotherapy has produced a notable objective response rate (35-40%) for metastatic HPV + cancers including Oropharyngeal Squamous Cell Carcinoma (OPSCC) and preclinical studies support the addition of an investigational HPV vaccine with therapeutic intent (PRGN-2009, a gorilla adenoviral based vaccine) to further increase anti-tumor efficacy.

Objectives:

Phase I in participants with recurrent/metastatic HPV positive cancer:

-Primary objective: To determine the safety and recommended phase II dose (RP2D) of PRGN-2009 (HPV vaccine) alone or in combination with M7824 administered at RP2D of 1200 mg every 2 weeks (q2w).

Phase II in participants with newly diagnosed stage I (T1, T2 N1)/II/III p16-positive oropharyngeal cancer and patients with newly diagnosed operable stage II/III/IVA/IVB/HPV + sinonasal squamous cell cancer:

-Primary objective: To determine if HPV vaccine alone (Arm 2A) is able to result in a >= 2-fold increase in cluster of differentiation 3 (CD3+) tumor infiltrating T cells post treatment compared with pre-treatment in p16-positive oropharyngeal cancer.

Eligibility:

Phase I:

  • Men or women of age >= 18 years old.
  • Subjects with cytologically or histologically confirmed locally advanced not amenable to potentially curative local therapies or metastatic HPV associated malignancies:

    • Cervical cancers;
    • p16+ Oropharyngeal cancers;
    • Anal cancers;
    • Vulvar, vaginal, penile, and squamous cell rectal cancers
    • Other locally advanced or metastatic solid tumors (e.g., lung, esophagus) that are known HPV+.
  • Prior first line systemic therapy is required

Phase II:

  • Men or women of age >= 18 years old.
  • Subjects with newly diagnosed stage I (T1, T2 N1), II or III, II or III p16-positive oropharyngeal squamous cell carcinoma (OPSCC) or stage II/III/IVA/IVB HPV-SNSCC planned for definitive therapy.

Design:

Phase I: Recurrent/metastatic HPV associated cancer:

  • A 3+3 dose escalation design will be used which will evaluate PRGN-2009 (HPV vaccine) at two dose levels (1x10\^11 and 5x10\^11 viral particle (VP) units) given as monotherapy followed by a third dose level evaluating the RP2D dose of PRGN-2009 in combination with 1200 mg (RP2D) of M7824. In addition, the combination of PRGN-2009 at RP2D with 1200 mg of M7824 will be expanded to a total of 10 evaluable participants to gauge the preliminary efficacy of the combination of PRGN-2009 and M7824 in participants with advanced disease.
  • There will be a 4-week dose limiting toxicity (DLT) evaluation period for each dose level.
  • It is expected that up to 22 participants may enroll.

Phase II:

Newly diagnosed p16-positive oropharyngeal cancer:

  • Evaluation of HPV vaccine alone (Arm 2A: Stage I (T1,T2 N1)/II/III) as neoadjuvant/ induction therapy before definitive standard of care therapy.
  • Participants will receive neoadjuvant/ induction immunotherapy at National Institutes of Health (NIH) Clinical Center and then be referred back to their home institution for definitive standard of care therapy.
  • It is expected that up to 20 participants may enroll.
  • Newly diagnosed stage II/III/IVA/IVB HPV-SNSCC:
  • Enrollment and treatment will occur similarly as participants with p16+oropharyngeal cancer for exploratory correlates to advise possible future trials. Up to 2 participants may enroll in this group.
03

Conditions studied

  • HPV Positive Cancer
  • Vulvar, Vaginal, Penile, Rectal Cancer
  • Anal Cancer
  • Oropharyngeal Cancer
  • Cervical Cancer

Keywords

  • HPV Associated Malignancy
  • Immunotherapy
  • HPV Vaccine
  • PRGN-2009
  • M7824
04

In context

Anus Neoplasms Reclassified

298 studies on the registry are indexed under Anus Neoplasms; 75 are open to participants now.

This study's enrollment of 39 is below the median of 65 across 212 interventional studies indexed under Anus Neoplasms.

Browse Anus Neoplasms studies →

Lead sponsor

National Cancer Institute (NCI) is the lead sponsor of 3,557 studies on the registry; 335 are open to participants now.

Of its 412 completed or terminated interventional studies of FDA-regulated products, 374 (91%) have results posted.

Compared within Anus Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Rectal Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects with or histologically confirmed locally advanced not amenable to potentially curative local therapies or human papillomavirus (HPV) associated (Phase I only):

    • Cervical cancers;
    • p16+ Oropharyngeal cancers;
    • Anal cancers;
    • Vulvar, vaginal, penile, and squamous cell rectal cancers;
    • Other locally advanced or metastatic solid tumors (e.g., lung, esophagus) that are known HPV+.
  • Subjects with cytologically or histologically confirmed newly diagnosed stage II or III p16-positive oropharyngeal squamous cell carcinoma planned for definitive therapy or with newly diagnosed stage II or III or IVA or IVB HPV-positive sinonasal squamous carcinoma (HPV-SNSCC) eligible for primary surgery (Phase II only).
  • Subjects must have , per (RECIST) 1.1 (Phase 1 only).
  • Phase I only: Participants must have received one in the recurrent/metastatic setting as well as checkpoint blockade therapy in tumors with Food and Drug Administration (FDA) approval (head and neck squamous cell cancer and programmed death-ligand 1 (PDL1+) cervical cancer). Exceptions to this include participants not eligible to receive standard therapy.
  • Men or Women; Age >=18 years.
  • (ECOG) performance status =\< 2
  • Adequate hematologic function at screening, as follows:

    • (ANC) >=1 x 109/L;
    • >= 9 g/dL;
    • >= 75,000/microliter.
  • Adequate renal and hepatic function at screening, as follows:

    • Serum creatinine =\< 1.5 x (ULN) OR Measured or calculated >= 40 mL/min for participant with creatinine levels > 1.5 X institutional ULN ( can also be used in place of creatinine or CrCl);
    • =\< 1.5 x ULN OR in subjects with Gilbert's syndrome, a total bilirubin =\< 3.0 x ULN;
    • (ALT) and aspartate aminotransferase (AST) =\< 2.5 x ULN, unless liver metastases are present, then values must be =\< 3 x ULN).
  • The effects of the immunotherapies (PRGN-2009 vaccine and M7824) on the developing human fetus are unknown. For this reason and because M7824 and PRGN-2009 used in this trial are possibly teratogenic, women of and men must agree to use highly effective (hormonal or barrier method of birth control; abstinence) prior to study entry and up to 2 months following the last dose of M7824 study treatment. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.
  • Participants serologically positive for (HIV), Hep B, Hep C are eligible as long as the viral loads are undetectable by quantitative polymerase chain reaction (PCR). HIV positive participants must have cluster of differentiation 4 (CD4) count >= 200 cells per cubic millimeter at enrollment, be on stable antiretroviral therapy for at least 4 weeks and have no reported opportunistic infections or Castleman's disease within 12 months prior to enrollment.

Exclusion criteria

EXCLUSION CRITERIA:

  • Participants with prior drug, , chemotherapy, immunotherapy or any prior radiotherapy (except for palliative bone directed therapy) within the past 28 days prior to the first drug administration except if the investigator has assessed that all residual treatment-related toxicities have resolved or are minimal and feel the participant is otherwise suitable for enrollment. Participants may continue hormonal therapy in the setting of a definitively treated cancer (e.g., breast).
  • Major surgery within 28 days prior to the first drug administration (minimally invasive procedures such as diagnostic are permitted).
  • Known active brain or central nervous system (less than a month out from definitive radiotherapy or surgery), seizures requiring anticonvulsant treatment (\<3 months) or cerebrovascular accident (\<3 months). In order to be eligible participants must have repeated central nervous system (CNS) imaging at least a month after definitive treatment showing stable CNS disease. Participants with evidence of intra-tumoral or peritumoral hemorrhage on baseline imaging are also excluded unless the hemorrhage is grade =\< 1 and has been shown to be stable on two consecutive imaging scans.
  • Pregnant women are excluded from this study because M7824 and PRGN-2009 vaccine have not been tested in pregnant women and there is potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with these immunotherapies, breastfeeding should be discontinued if the mother is treated on this protocol.
  • Only for Phase I, Arm 1B: Active disease that might deteriorate when receiving an immunostimulatory agent with exception of:

    • Diabetes type I, eczema, vitiligo, alopecia, psoriasis, hypo- or hyperthyroid disease or other mild autoimmune disorders not requiring treatment;
    • Administration of for other conditions through a route known to result in a minimal systemic exposure (topical, intranasal, intro-ocular, or inhalation) is acceptable;
    • Subjects on systemic intravenous or oral corticosteroid therapy with the exception of

physiologic doses of corticosteroids (=\< the equivalent of prednisone 10 mg/day) or other immunosuppressors such as azathioprine or cyclosporin A are excluded on the basis of potential immune suppression. For these subjects these excluded treatments must be discontinued at least 1 weeks prior to enrollment for recent short course use (=\< 14 days) or discontinued at least 4 weeks prior to enrollment for long term use (> 14 days). In addition, the use of corticosteroids as premedication for contrast-enhanced studies is allowed prior to enrollment and on study.

  • Only for Phase I: Subjects with a history of serious intercurrent chronic or acute illness, such as cardiac or pulmonary disease, hepatic disease, bleeding diathesis or recent (within 3 months) clinically significant bleeding events, known \<50% (confirmation of ejection fraction (EF) > 50% is not required for eligibility), history of myocarditis, or recent myocardial infarction (within 6 months), or other illness considered by the Investigator as high risk for M7824 drug treatment.
  • Only for Phase I: Subjects refusing to accept blood products as medically indicated.
  • History of second within 3 years of enrollment except for the following: adequately treated localized skin cancer, cervical carcinoma in situ, superficial bladder cancer, other localized malignancy which has been adequately treated or malignancy which does not require active systemic treatment (e.g., low risk chronic lymphocytic leukemia (CLL)). For participants enrolled on the phase I portion of the protocol a second HPV driven malignancy is allowed.
  • Only for Phase I, Arm 1B: Subjects with a known severe reaction to monoclonal antibodies or its (grade >/= 3 National Cancer Institute (NCI)- (CTCAE) v5) will be evaluated by the allergy/immunology team prior to enrollment.
  • Prior allogenic tissue/solid organ transplant.
  • For participants who may receive M7824: previous life-threatening side effects resulting from prior therapy.
  • Participants with pulse oximetry \< 92% on room air at screening.
  • Participants unable to provide .
  • Participants whose inclusion in the trial would in the judgement of the principal investigator (PI) lead to time from diagnosis to initiation of curative treatment of>70 days (Arm 2A only).
Terms in these criteria, in plain language(32)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

06

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
39 participants (actual)

Study arms

  • Experimental
    1/Arm 1A

    Human Papillomavirus Vaccine (HPV) vaccine at 1x10(11) Viral Particles (VP) Dose Level 1 (DL1) and at 5x10(11) VP Dose Level 2 (DL2)

    Biological: PRGN-2009 · Diagnostic Test: EKG · Diagnostic Test: CT Scan · Diagnostic Test: Brain MRI · Procedure: Biopsy

  • Experimental
    2/Arm 1B

    Human Papillomavirus Vaccine (HPV) vaccine at recommended phase 2 dose (RP2D) plus M7824 at 1200 mg.

    Biological: PRGN-2009 · Biological: M7824 · Diagnostic Test: EKG · Diagnostic Test: CT Scan · Diagnostic Test: Brain MRI · Procedure: Biopsy

  • Experimental
    3/Arm 2A

    Human Papillomavirus Vaccine (HPV) vaccine at recommended phase 2 dose (RP2D) given as neoadjuvant or induction therapy.

    Biological: PRGN-2009 · Diagnostic Test: EKG · Diagnostic Test: CT Scan · Diagnostic Test: Brain MRI · Procedure: Biopsy

  • Experimental
    4/Arm 2B

    Human Papillomavirus Vaccine (HPV) vaccine at recommended phase 2 dose (RP2D) plus M7824 at 1200 mg given as neoadjuvant or induction therapy.

    Biological: PRGN-2009 · Biological: M7824 · Diagnostic Test: EKG · Diagnostic Test: CT Scan · Diagnostic Test: Brain MRI · Procedure: Biopsy

Interventions

  • BiologicalGorilla-derived Adenovirus-expressing HPV-16/18 E6/E7 VaccineStudies of Gorilla-derived Adenovirus-expressing HPV-16/18 E6/E7 VaccineGorilla-derived Adenovirus-expressing HPV-16/18 E6/E7 Vaccine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    On the phase I portion of the protocol PRGN-2009 will be administered on Day (D)1, D15, D29 followed by booster vaccines every 4 weeks for up to a year. The dose level given as booster will be the same dose participants will be receiving for D1, D15 and D29. On the phase II portion of the protocol PRGN-2009 will be administered on just D1 and D15.

  • BiologicalBintrafusp alfaStudies of Bintrafusp alfaBintrafusp alfa pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Subjects enrolled to Arm 1B will receive M7824 (MSB0011359C) via intravenous (IV) infusion over 1 hour (-10 minutes / +20 minutes, that is, over 50 to 80 minutes) once every 2 weeks. M7824 will be administered as a "flat" dose of 1,200 mg independent of body weight. M7824 is administered as an intravenous infusion with a mandatory 0.2 micron in-line filter.

    Also known as: MSB0011359C

  • Diagnostic testEKG

    Screening, end of treatment and safety follow-up.

    Also known as: Electrocardiogram

  • Diagnostic testCT Scan

    Brain CT Scan at Baseline. Tumor evaluations CT Scan (Screening, Baseline/Day 1, and odd numbered Weeks (Week 1, Week 3, Week 5, and Week 7 onwards).

    Also known as: Computed tomography scan

  • Diagnostic testBrain MRI

    Brain MRI at Baseline. Tumor evaluations MRI (Screening, Baseline/Day 1, and odd numbered weeks (Week 1, Week 3, Week 5, and Week 7 onwards).

    Also known as: Brain magnetic resonance imaging

  • ProcedureBiopsy

    Biopsy for immune analysis: Baseline/Day 1, and odd numbered Weeks (Week 1, Week 3, Week 5, and Week 7 onwards).

    Also known as: Bx

07

What researchers measure

Primary outcomes

  1. Phase I: Recommended Phase II Dose of PRGN-2009

    Phase I: To determine the recommended phase II dose (RP2D) of PRGN-2009 Human Papillomavirus Vaccine (HPV) vaccine alone or in combination with M7824 (MSB0011359C). Recommended Phase 2 Dose, the dose of a drug or drug combination that was identified in a Phase 1 study (dose finding study) that was identified for continued study.

    Time frame: Date treatment consent signed to date off study, approximately 18 months

  2. Phase I: Safety - Number of Treatment-related Serious Adverse Events (AE) of Grades 1, 2, 3, 4 and/or 5 Along With the AE Term

    Adverse events were assessed by the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. Grade 1 is mild. Grade 2 is moderate. Grade 3 is severe. Grade 4 is life-threatening. Grade 5 is death related to adverse event. All participants who receive any investigational treatment will be evaluable for safety and toxicity evaluations.

    Time frame: Date treatment consent signed to date off study, an average of 6 months

  3. Phase II: Percentage of Participants That Had a 2-fold Increase of Cluster of Differentiation 3 (CD3+) Tumor Infiltrating T Cells in Biopsies Performed Post-treatment Compared to Pre-treatment

    CD3+ tumor infiltrating T cells post treatment compared with pre-treatment reported with a 95% confidence interval assessed by multiplex CD3+ tumor infiltrating lymphocytes assessed by multiplex immunofluorescence from the surgical/ biopsy tissue collected pre- and post-treatment. The percentage of participants with doubling of baseline CD3+ tumor infiltrating lymphocytes will be provided as well as the 95% confidence interval. The CD3 cells are assessed by multiplex immunofluorescence in the biopsies. Doubling is the desired outcome.

    Time frame: Pre-Treatment (Baseline) and anytime between Week 4-5 post treatment

Secondary outcomes

  1. Phase I: Proportion of Participants That Are Hospitalized Because of Adverse Events Attributed to Disease Progression

    Phase I: proportion of participants that are hospitalized because of adverse events attributed to disease progression. Adverse events were assessed by the Common Terminology Criteria for Adverse Events(CTCAE v5.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. Disease progression was assessed by the Response Evaluation Criteria in Solid Tumors(RECIST) and is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study. The appearance of one or more new lesions is also considered progression.

    Time frame: Date treatment consent signed to date of progression, an average of 6 months

  2. Phase II: 3-year Overall Survival for PRGN-2009 Alone

    Phase II: Overall survival assessed using the Kaplan-Meier method, defined as the time from the date of first treatment to the date of death (any cause). Participants who receive two doses of PRGN-2009 and go on to receive standard definitive therapy will be evaluable for overall survival assessment.

    Time frame: 3 years

  3. Phase II: 3 Year Relapse-free Survival for PRGN-2009 Alone

    Phase II: 3-year Relapse-free survival assessed using the Kaplan-Meier method, defined as the time from completion of standard of care definitive therapy to the date of disease recurrence or death (any cause) whichever occurs first. Participants who receive two doses of PRGN-2009 and go on to receive standard definitive therapy will be evaluable for overall survival assessment.

    Time frame: 3 years

  4. Phase I: Overall Survival (OS)

    Phase I: Overall survival assessed using the Kaplan-Meier method, defined as the time from the date of first treatment to the date of death (any cause). Participants who are alive at the end of follow up will be censored at the last known date alive.

    Time frame: The time from the date of first treatment to the date of death (any cause), an average of 12 months

  5. Phase I: Progression-free Survival Time (PFS)

    PFS, evaluated using Kaplan-Meier methods, defined as the time from the date of first treatment to the date of disease progression or death (any cause) whichever occurs first. Disease progression assessed by the Response Evaluation Criteria in Solid Tumors (RECIST), is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). The appearance of one or more new lesions is also considered progression.

    Time frame: Date of first treatment to date of disease progression or death (any cause), an average of 6 months

  6. Phase I: Duration of Response (DOR)

    Phase 1: DOR is measured from the time measurement criteria are met for Complete Response (CR) or Partial Response (PR) (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented (taking as reference for progressive disease the smallest measurements recorded since the treatment started). Response was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST). CR is disappearance of all target lesions. PR is at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum of diameters. Disease progression is at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). The appearance of one or more new lesions is also considered progression.

    Time frame: Date of first treatment to date of disease progression or death (any cause), an average of 4 months

  7. Phase II: Safety - Number of Treatment-related Serious Adverse Events (AE) of Grades 1, 2, 3, 4 and/or 5 Along With the AE Term

    Phase II: Adverse events were assessed by the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. Grade 1 is mild. Grade 2 is moderate. Grade 3 is severe. Grade 4 is life-threatening. Grade 5 is death related to adverse event. All participants who receive any investigational treatment will be evaluable for safety and toxicity evaluations.

    Time frame: Date treatment consent signed up to 28 days after last treatment

  8. Phase II: Overall Survival at 3 Years Compared With Historical Cohort

    Phase II: Assess if PRGN-2009 results in significantly prolonged survival at three years as compared to the expected 80% three-year historical survival in p16-positive oropharyngeal cancer (OPC) participants. Three-year overall survival will be measured using a Kaplan-Meier curve and will be compared descriptively with the historical benchmark. Participants who receive two doses of PRGN-2009 and go on to receive standard definitive therapy will be evaluable for overall survival assessment.

    Time frame: 3 years

  9. Phase I: Overall Response Rate (ORR)

    Phase 1: overall response rate (ORR) accessed according to the Response Evaluation Criteria in Solid Tumors (RECIST)1.1., defined as a complete response or partial response assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Complete response is disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. Partial response is at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum of diameters.

    Time frame: study end, an average of 6 months

Other outcomes

  1. Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0)

    Here is the number of participants with serious and/or non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.

    Time frame: Date treatment consent signed to date off study, approximately 27 months and 1 day, 9 months and 9 days, 30 months and 11 days, and 9 days for each group respectively.

  2. Phase I: Number of Participants With Dose-Limiting Toxicities (DLT)

    DLT is defined as any one of the following adverse events, possibly attributable to study drugs, that occur within 28 days of the human papillomavirus (HPV) vaccine monotherapy or 28 days of starting the HPV vaccine + M7824 (MSB0011359C) combination therapy: any grade 3 or higher bleeding episode requiring blood transfusion(s); Any Grade 4 or \> adverse drug reactions (ADRs) as defined by the Common Terminology Criteria for Adverse Events (CTCAE) v5.0 and assessed as possibly related to any agent by the Investigator, except for laboratory values that are asymptomatic or resolve to Grade ≤ 1 or baseline grade within 7 days without medical intervention; discontinuation any Grade 3 ADRs possibly attributed to any agent except for any of the following: Grade 3 flu-like symptoms or fever, as well as associated symptoms of fatigue, headaches, nausea, emesis which can be controlled with conservative medical management. See Protocol for details.

    Time frame: Dose-Limiting Toxicities (DLT) were monitored/assessed from the time of first drug administration through 28 days after starting the trial treatment.

08

Results

Posted Aug 18, 2026

Participant flow

Participant flow — Overall Study
MilestonePhase I Cohort 1, Arm 1A, Dose Level 1Phase I Cohort 1A, Arm 1A, Dose Level 2Phase I Cohort 1, Arm 1B, Dose Level 2Phase II Cohort 2, Arm 2A, Dose Level 2
Started331122
Completed10122
Not completed23100
Withdrew: Disease progression2390
Withdrew: Death0010

Outcome measures

PrimaryPhase I: Recommended Phase II Dose of PRGN-2009

Phase I: To determine the recommended phase II dose (RP2D) of PRGN-2009 Human Papillomavirus Vaccine (HPV) vaccine alone or in combination with M7824 (MSB0011359C). Recommended Phase 2 Dose, the dose of a drug or drug combination that was identified in a Phase 1 study (dose finding study) that was identified for continued study.

Time frame:
Date treatment consent signed to date off study, approximately 18 months
Reported as:
Number · viral particles (VP)
Phase I: Recommended Phase II Dose of PRGN-2009
viral particles (VP)All Participants in Phase I
Phase I: Recommended Phase II Dose of PRGN-2009500,000,000,000
PrimaryPhase I: Safety - Number of Treatment-related Serious Adverse Events (AE) of Grades 1, 2, 3, 4 and/or 5 Along With the AE Term

Adverse events were assessed by the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. Grade 1 is mild. Grade 2 is moderate. Grade 3 is severe. Grade 4 is life-threatening. Grade 5 is death related to adverse event. All participants who receive any investigational treatment will be evaluable for safety and toxicity evaluations.

Time frame:
Date treatment consent signed to date off study, an average of 6 months
Reported as:
Number · adverse events
Phase I: Safety - Number of Treatment-related Serious Adverse Events (AE) of Grades 1, 2, 3, 4 and/or 5 Along With the AE Term
adverse eventsPhase I Cohort 1, Arm 1A, Dose Level 1Phase I Cohort 1A, Arm 1A, Dose Level 2Phase I Cohort 1, Arm 1B, Dose Level 2
Any Grade 1000
Any Grade 2000
Grade 3 Duodenal hemorrhage001
Grade 4 Duodenal hemorrhage001
Grade 4 Pharyngeal mucositis001
Any Grade 5000
PrimaryPhase II: Percentage of Participants That Had a 2-fold Increase of Cluster of Differentiation 3 (CD3+) Tumor Infiltrating T Cells in Biopsies Performed Post-treatment Compared to Pre-treatment

CD3+ tumor infiltrating T cells post treatment compared with pre-treatment reported with a 95% confidence interval assessed by multiplex CD3+ tumor infiltrating lymphocytes assessed by multiplex immunofluorescence from the surgical/ biopsy tissue collected pre- and post-treatment. The percentage of participants with doubling of baseline CD3+ tumor infiltrating lymphocytes will be provided as well as the 95% confidence interval. The CD3 cells are assessed by multiplex immunofluorescence in the biopsies. Doubling is the desired outcome.

Time frame:
Pre-Treatment (Baseline) and anytime between Week 4-5 post treatment
Reported as:
Number · Percentage of Participants
Phase II: Percentage of Participants That Had a 2-fold Increase of Cluster of Differentiation 3 (CD3+) Tumor Infiltrating T Cells in Biopsies Performed Post-treatment Compared to Pre-treatment
Percentage of ParticipantsPhase II Cohort 2, Arm 2A, Dose Level 2
Phase II: Percentage of Participants That Had a 2-fold Increase of Cluster of Differentiation 3 (CD3+) Tumor Infiltrating T Cells in Biopsies Performed Post-treatment Compared to Pre-treatment12.5 (3.5 to 36.0)
SecondaryPhase I: Proportion of Participants That Are Hospitalized Because of Adverse Events Attributed to Disease Progression

Phase I: proportion of participants that are hospitalized because of adverse events attributed to disease progression. Adverse events were assessed by the Common Terminology Criteria for Adverse Events(CTCAE v5.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. Disease progression was assessed by the Response Evaluation Criteria in Solid Tumors(RECIST) and is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study. The appearance of one or more new lesions is also considered progression.

Time frame:
Date treatment consent signed to date of progression, an average of 6 months
Reported as:
Number · proportion of participants
Phase I: Proportion of Participants That Are Hospitalized Because of Adverse Events Attributed to Disease Progression
proportion of participantsPhase I Cohort 1, Arm 1A, Dose Level 1Phase I Cohort 1A, Arm 1A, Dose Level 2Phase I Cohort 1, Arm 1B, Dose Level 2
Phase I: Proportion of Participants That Are Hospitalized Because of Adverse Events Attributed to Disease Progression0.6600
SecondaryPhase II: 3-year Overall Survival for PRGN-2009 Alone

Phase II: Overall survival assessed using the Kaplan-Meier method, defined as the time from the date of first treatment to the date of death (any cause). Participants who receive two doses of PRGN-2009 and go on to receive standard definitive therapy will be evaluable for overall survival assessment.

Time frame:
3 years
Reported as:
Number · Percentage of participants
Phase II: 3-year Overall Survival for PRGN-2009 Alone
Percentage of participantsPhase II Cohort 2, Arm 2A, Dose Level 2
Phase II: 3-year Overall Survival for PRGN-2009 Alone95 (87 to 100)
SecondaryPhase II: 3 Year Relapse-free Survival for PRGN-2009 Alone

Phase II: 3-year Relapse-free survival assessed using the Kaplan-Meier method, defined as the time from completion of standard of care definitive therapy to the date of disease recurrence or death (any cause) whichever occurs first. Participants who receive two doses of PRGN-2009 and go on to receive standard definitive therapy will be evaluable for overall survival assessment.

Time frame:
3 years
Reported as:
Number · Percentage of participants
Phase II: 3 Year Relapse-free Survival for PRGN-2009 Alone
Percentage of participantsPhase II Cohort 2, Arm 2A, Dose Level 2
Phase II: 3 Year Relapse-free Survival for PRGN-2009 Alone77 (62 to 97)
SecondaryPhase I: Overall Survival (OS)

Phase I: Overall survival assessed using the Kaplan-Meier method, defined as the time from the date of first treatment to the date of death (any cause). Participants who are alive at the end of follow up will be censored at the last known date alive.

Time frame:
The time from the date of first treatment to the date of death (any cause), an average of 12 months
Reported as:
Median · Months
Phase I: Overall Survival (OS)
MonthsPhase I Cohort 1, Arm 1A, Dose Level 1Phase I Cohort 1A, Arm 1A, Dose Level 2Phase I Cohort 1, Arm 1B, Dose Level 2
Phase I: Overall Survival (OS)20.4 (2.9 to 26.8)7.0 (6.5 to 7.8)19.1 (0.5 to 55.2)
SecondaryPhase I: Progression-free Survival Time (PFS)

PFS, evaluated using Kaplan-Meier methods, defined as the time from the date of first treatment to the date of disease progression or death (any cause) whichever occurs first. Disease progression assessed by the Response Evaluation Criteria in Solid Tumors (RECIST), is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). The appearance of one or more new lesions is also considered progression.

Time frame:
Date of first treatment to date of disease progression or death (any cause), an average of 6 months
Reported as:
Median · Months
Phase I: Progression-free Survival Time (PFS)
MonthsPhase I Cohort 1, Arm 1A, Dose Level 1Phase I Cohort 1A, Arm 1A, Dose Level 2Phase I Cohort 1, Arm 1B, Dose Level 2
Phase I: Progression-free Survival Time (PFS)3.6 (2.3 to 16.8)1.8 (1.8 to 3.6)1.8 (0.5 to 18.1)
SecondaryPhase I: Duration of Response (DOR)

Phase 1: DOR is measured from the time measurement criteria are met for Complete Response (CR) or Partial Response (PR) (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented (taking as reference for progressive disease the smallest measurements recorded since the treatment started). Response was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST). CR is disappearance of all target lesions. PR is at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum of diameters. Disease progression is at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). The appearance of one or more new lesions is also considered progression.

Time frame:
Date of first treatment to date of disease progression or death (any cause), an average of 4 months
Reported as:
Median · Months
Phase I: Duration of Response (DOR)
MonthsPhase I Cohort 1, Arm 1A, Dose Level 1Phase I Cohort 1A, Arm 1A, Dose Level 2Phase I Cohort 1, Arm 1B, Dose Level 2
Phase I: Duration of Response (DOR)NA (NA to NA)NA (NA to NA)10.1 (8.0 to 12.2)
SecondaryPhase II: Safety - Number of Treatment-related Serious Adverse Events (AE) of Grades 1, 2, 3, 4 and/or 5 Along With the AE Term

Phase II: Adverse events were assessed by the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. Grade 1 is mild. Grade 2 is moderate. Grade 3 is severe. Grade 4 is life-threatening. Grade 5 is death related to adverse event. All participants who receive any investigational treatment will be evaluable for safety and toxicity evaluations.

Time frame:
Date treatment consent signed up to 28 days after last treatment
Reported as:
Number · Adverse events
Phase II: Safety - Number of Treatment-related Serious Adverse Events (AE) of Grades 1, 2, 3, 4 and/or 5 Along With the AE Term
Adverse eventsPhase II Cohort 2, Arm 2A, Dose Level 2
Any Grade 10
Any Grade 20
Any Grade 30
Any Grade 40
Any Grade 50
SecondaryPhase II: Overall Survival at 3 Years Compared With Historical Cohort

Phase II: Assess if PRGN-2009 results in significantly prolonged survival at three years as compared to the expected 80% three-year historical survival in p16-positive oropharyngeal cancer (OPC) participants. Three-year overall survival will be measured using a Kaplan-Meier curve and will be compared descriptively with the historical benchmark. Participants who receive two doses of PRGN-2009 and go on to receive standard definitive therapy will be evaluable for overall survival assessment.

Time frame:
3 years
Reported as:
Number · Percentage of participants
Phase II: Overall Survival at 3 Years Compared With Historical Cohort
Percentage of participantsPhase II Cohort 2, Arm 2A, Dose Level 2
Phase II: Overall Survival at 3 Years Compared With Historical Cohort95
SecondaryPhase I: Overall Response Rate (ORR)

Phase 1: overall response rate (ORR) accessed according to the Response Evaluation Criteria in Solid Tumors (RECIST)1.1., defined as a complete response or partial response assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Complete response is disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. Partial response is at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum of diameters.

Time frame:
study end, an average of 6 months
Reported as:
Count of participants · Participants
Phase I: Overall Response Rate (ORR)
ParticipantsPhase I Cohort 1, Arm 1A, Dose Level 1Phase I Cohort 1A, Arm 1A, Dose Level 2Phase I Cohort 1, Arm 1B, Dose Level 2
Phase I: Overall Response Rate (ORR)002
Other pre-specifiedNumber of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0)

Here is the number of participants with serious and/or non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.

Time frame:
Date treatment consent signed to date off study, approximately 27 months and 1 day, 9 months and 9 days, 30 months and 11 days, and 9 days for each group respectively.
Reported as:
Count of participants · Participants
Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0)
ParticipantsPhase I Cohort 1, Arm 1A, Dose Level 1Phase I Cohort 1A, Arm 1A, Dose Level 2Phase I Cohort 1, Arm 1B, Dose Level 2Phase II Cohort 2, Arm 2A, Dose Level 2
Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0)331122
Other pre-specifiedPhase I: Number of Participants With Dose-Limiting Toxicities (DLT)

DLT is defined as any one of the following adverse events, possibly attributable to study drugs, that occur within 28 days of the human papillomavirus (HPV) vaccine monotherapy or 28 days of starting the HPV vaccine + M7824 (MSB0011359C) combination therapy: any grade 3 or higher bleeding episode requiring blood transfusion(s); Any Grade 4 or \> adverse drug reactions (ADRs) as defined by the Common Terminology Criteria for Adverse Events (CTCAE) v5.0 and assessed as possibly related to any agent by the Investigator, except for laboratory values that are asymptomatic or resolve to Grade ≤ 1 or baseline grade within 7 days without medical intervention; discontinuation any Grade 3 ADRs possibly attributed to any agent except for any of the following: Grade 3 flu-like symptoms or fever, as well as associated symptoms of fatigue, headaches, nausea, emesis which can be controlled with conservative medical management. See Protocol for details.

Time frame:
Dose-Limiting Toxicities (DLT) were monitored/assessed from the time of first drug administration through 28 days after starting the trial treatment.
Reported as:
Count of participants · Participants
Phase I: Number of Participants With Dose-Limiting Toxicities (DLT)
ParticipantsPhase I Cohort 1, Arm 1A, Dose Level 1Phase I Cohort 1A, Arm 1A, Dose Level 2Phase I Cohort 1, Arm 1B, Dose Level 2
Phase I: Number of Participants With Dose-Limiting Toxicities (DLT)001

Adverse events

Collected over All-Cause Mortality is assessed from the time of first drug administration through the date of death (any cause) or up to 5 years. Adverse Events were monitored/assessed from the time of first drug administration through 28 days after the last drug administration, an average of 6 months.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Phase I Cohort 1, Arm 1A, Dose Level 13/3 (100%)2/3 (66.7%)3/3 (100%)
Phase I Cohort 1A, Arm 1A, Dose Level 23/3 (100%)1/3 (33.3%)3/3 (100%)
Phase I Cohort 1, Arm 1B, Dose Level 29/11 (81.8%)3/11 (27.3%)11/11 (100%)
Phase II Cohort 2, Arm 2A, Dose Level 23/22 (13.6%)0/22 (0%)22/22 (100%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventPhase I Cohort 1, Arm 1A, Dose Level 1Phase I Cohort 1A, Arm 1A, Dose Level 2Phase I Cohort 1, Arm 1B, Dose Level 2Phase II Cohort 2, Arm 2A, Dose Level 2
Colonic obstructionGastrointestinal disorders1/30/30/110/22
HeadacheNervous system disorders1/30/30/110/22
HypoglycemiaMetabolism and nutrition disorders0/31/30/110/22
MalaiseGeneral disorders1/30/30/110/22
Renal and urinary disorders - Other, Obstructive Acute Kidney Injury,NephrostomyRenal and urinary disorders1/30/30/110/22
SepsisInfections and infestations1/30/30/110/22
Urinary tract infectionInfections and infestations1/30/30/110/22
Duodenal hemorrhageGastrointestinal disorders0/30/32/110/22
AnemiaBlood and lymphatic system disorders0/30/31/110/22
Death NOSGeneral disorders0/30/31/110/22
Most frequent other events
Showing 10 of 83
Most frequent other events
EventPhase I Cohort 1, Arm 1A, Dose Level 1Phase I Cohort 1A, Arm 1A, Dose Level 2Phase I Cohort 1, Arm 1B, Dose Level 2Phase II Cohort 2, Arm 2A, Dose Level 2
Injection site reactionGeneral disorders3/31/39/1116/22
Flu like symptomsGeneral disorders2/31/36/1117/22
AnemiaBlood and lymphatic system disorders2/31/33/112/22
ConstipationGastrointestinal disorders1/32/31/111/22
FatigueGeneral disorders2/30/34/115/22
NauseaGastrointestinal disorders2/31/32/113/22
VomitingGastrointestinal disorders1/32/30/110/22
Rash maculo-papularSkin and subcutaneous tissue disorders1/30/34/110/22
Abdominal painGastrointestinal disorders1/31/33/110/22
Alkaline phosphatase increasedInvestigations0/31/31/110/22

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Phase I Cohort 1, Arm 1A, Dose Level 1Phase I Cohort 1A, Arm 1A, Dose Level 2Phase I Cohort 1, Arm 1B, Dose Level 2Phase II Cohort 2, Arm 2A, Dose Level 2Total
<=18 years00000
Between 18 and 65 years2261727
>=65 years115512
Age, Continuous
Age, Continuous(years)Phase I Cohort 1, Arm 1A, Dose Level 1Phase I Cohort 1A, Arm 1A, Dose Level 2Phase I Cohort 1, Arm 1B, Dose Level 2Phase II Cohort 2, Arm 2A, Dose Level 2Total
Mean58.47 ± 13.6459.13 ± 8.0664.84 ± 8.9559.67 ± 7.8960.99 ± 8.65
Sex: Female, Male
Sex: Female, Male(Participants)Phase I Cohort 1, Arm 1A, Dose Level 1Phase I Cohort 1A, Arm 1A, Dose Level 2Phase I Cohort 1, Arm 1B, Dose Level 2Phase II Cohort 2, Arm 2A, Dose Level 2Total
Female333312
Male0081927
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Phase I Cohort 1, Arm 1A, Dose Level 1Phase I Cohort 1A, Arm 1A, Dose Level 2Phase I Cohort 1, Arm 1B, Dose Level 2Phase II Cohort 2, Arm 2A, Dose Level 2Total
Hispanic or Latino00000
Not Hispanic or Latino33112138
Unknown or Not Reported00011
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Phase I Cohort 1, Arm 1A, Dose Level 1Phase I Cohort 1A, Arm 1A, Dose Level 2Phase I Cohort 1, Arm 1B, Dose Level 2Phase II Cohort 2, Arm 2A, Dose Level 2Total
American Indian or Alaska Native00000
Asian10001
Native Hawaiian or Other Pacific Islander00000
Black or African American12238
White1191829
More than one race00000
Unknown or Not Reported00011
Region of Enrollment
Region of Enrollment(participants)Phase I Cohort 1, Arm 1A, Dose Level 1Phase I Cohort 1A, Arm 1A, Dose Level 2Phase I Cohort 1, Arm 1B, Dose Level 2Phase II Cohort 2, Arm 2A, Dose Level 2Total
United States33112239
09

Study locations

1 site
  • National Institutes of Health Clinical Center
    Bethesda, Maryland 20892, United States
10

References and documents

Publications

  • Floudas CS, Goswami M, Donahue RN, Strauss J, Pastor DM, Redman JM, Brownell I, Turkbey EB, Steinberg SM, Cordes LM, Marte JL, Khan MH, McMahon S, Lamping E, Manu M, Manukyan M, Brough DE, Lankford A, Jochems C, Schlom J, Gulley JL. PRGN-2009 and bintrafusp alfa for patients with advanced or metastatic human papillomavirus-associated cancer. Cancer Immunol Immunother. 2025 Mar 21;74(5):155. doi: 10.1007/s00262-025-04009-z. PubMed 40116923 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — All individual participant data (IPD) recorded in the medical record will be shared with intramural investigators upon request. In addition, all large-scale genomic sequencing data will be shared with subscribers to the database of Genotypes and Phenotypes (dbGaP).

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Clinical data available during the study and indefinitely. Genomic data are available once genomic data are uploaded per protocol Genomic Data Sharing (GDS) plan for as long as database is active.

Access criteria: Clinical data will be made available via subscription to Biomedical Translational Research Information System (BTRIS) and with the permission of the study principal investigator (PI). Genomic data are made available via the database of Genotypes and Phenotypes (dbGaP) through requests to the data custodians.

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2020 to primary completion in Nov 2022, 27 months.

Results were first posted in Aug 2026, 3 years 8 months after primary completion. A results delay was requested in Nov 2023.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 13, 2020
First posted
Jun 16, 2020
StartActual
Aug 11, 2020
Primary completionActual
Nov 22, 2022
CompletionActual
Mar 31, 2026
Results delay requested
Nov 15, 2023
Results first posted
Aug 18, 2026
Last update
Aug 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT04432597
Responsible party
Charalampos Floudas, MD, DMSc, MS (Principal Investigator, National Cancer Institute (NCI)) — Principal investigator
First posted
Jun 16, 2020
Start date
Aug 11, 2020
Primary completion
Nov 22, 2022
Completion
Mar 31, 2026
Results posted
Aug 18, 2026
Last update
Aug 18, 2026

Study contacts

Charalampos Floudas, M.D.
principal investigator · National Cancer Institute (NCI)

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gorilla-derived Adenovirus-expressing HPV-16/18 E6/E7 Vaccine

Start the discussion